Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination

Frontiers in Immunology

Immunology

Cecilia L. Moore¹  Margareth Dalcolmo²  Tenaya Jamieson³  Nicole L. Messina⁴  Laure F. Pittet⁵  Nigel Curtis⁵  Bruno Jardim⁶  Marcus V. G. Lacerda⁶  Glauce dos Santos⁷  Mariana G. Sperotto⁸  Marco A. M. Puga⁸  Patricia V. da Silva⁸  Julio Croda⁹  Roberto D. de Oliveira^1,10 

[1] Clinical Epidemiology and Biostatistics Unit, Murdoch Children’s Research Institute, Parkville, VIC, Australia;Helio Fraga Reference Center, Oswaldo Cruz Foundation Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil;Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil;Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children’s Research Institute, Parkville, VIC, Australia;Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children’s Research Institute, Parkville, VIC, Australia;Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia;Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children’s Research Institute, Parkville, VIC, Australia;Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia;Infectious Diseases, The Royal Children’s Hospital Melbourne, Parkville, VIC, Australia;Institute of Clinical Research Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil;National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil;School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil;Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil;School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil;Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil;Yale School of Public Health, New Haven, CT, United States;State University of Mato Grosso do Sul, Dourados-Mato Grosso do Sul, Brazil;Federal University of Grande Dourados, Dourados, Brazil;

关键词: vaccine;    COVID-19;    antibody;    ChAdOx1-S;    CoronaVac;    BCG;   

DOI  :  10.3389/fimmu.2023.1172851

 received in 2023-02-24, accepted in 2023-06-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.

【 授权许可】

Unknown   
Copyright © 2023 Messina, Sperotto, Puga, da Silva, de Oliveira, Moore, Pittet, Jamieson, Dalcolmo, dos Santos, Jardim, Lacerda, Curtis and Croda